Despite worsening prematurity birth rate, odds of survival improving with NICU adoption of Prolacta's 100% human milk-based fortifiers
Type: Press Releases
Topic(s): Growth Mortality Neurodevelopmental Outcomes
Study Reveals an Exclusive Human Milk Diet With Prolact+ H2MF, Prolacta’s 100% Breastmilk-Based Fortifier, Substantially Reduces Costs Due to Complications in the NICU
Type: Press Releases
Topic(s): Cost Savings / Cost Effectiveness
Prolacta Bioscience Launches Women’s Leadership Development Academy
Type: Press Releases
Topic(s): Company
Preemie Health Expert Dr. Melinda Elliott Named Chief Medical Officer of Prolacta Bioscience
Type: Press Releases
Topic(s): Company
Smallest Preemies Can Achieve Catch-Up Growth by 2 Years of Age with Exclusive Human Milk Diet New Study Finds
Type: Press Releases
Topic(s): Growth Long-Term outcomes
Prolacta Bioscience® to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019
Type: Press Releases
Topic(s): Conferences and Events
Growing Number of Hospital NICUs Turning to Prolacta’s 100 Percent Human Milk-Based Nutrition for the Premature Infants in Their Care
Type: Press Releases
Topic(s): Clinical Studies on Prolact/Humavant CR Company Cost Savings / Cost Effectiveness
Prolacta Bioscience® to Provide Perspective on the Needs of Newborns With Heart Defects
Type: Press Releases
Topic(s): Single Ventricle Congenital Heart Defects (SVP )
Prolacta Bioscience Doubles Expiration Time and Simplifies Use of Prolact CR® Human Milk-Based Caloric Fortifier
Type: Press Releases
Topic(s): Company Healthcare Professionals Product
